Phosphotyrosine amide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Phosphotyrosine amide
• 英文别名: [4-[(2S)-2,3-diamino-3-oxopropyl]phenyl] dihydrogen phosphate
• 化学式: C₉H₁₃N₂O₅P
• 分子量: 260.18
• InChiKey: SPABWCQEXYNRKM-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Competitive immunoassay
  申请人：Beechem Joseph

  公开号：US20060160068A1

  公开（公告）日：2006-07-20

  The present invention provides ligand-detection reagents, ligand analogs and methods for determining the presence of a ligand in a sample. The ligand-detection reagent comprises a ligand-binding antibody and a ligand analog to form an antibody-ligand analog complex wherein the ligand analog is covalently bonded to a reporter molecule. This complex may additionally comprise a labeling protein non-covalently bonded to the antibody to form a ternary complex wherein the labeling protein comprises a monovalent antibody fragment or a non-antibody protein that is covalently bonded to a label moiety. The reporter molecule is either quenched by the ligand-binding antibody or by the label moiety of the labeling protein, depending on the reporter molecule and the ligand-binding antibody, wherein the amount of quenching is directly related to the amount of ligand present in the sample. Alternatively, the ligand analog is fluorogenic wherein the ligand analog is essentially non-fluorescent in solution but when bound by the ligand-binding antibody the detectable signal increases. In this instance a decrease in signal, as opposed to the relieving of quenching, is measured for the presence of a target ligand.

  本发明提供了配体检测试剂、配体类似物和用于确定样品中配体存在的方法。该配体检测试剂包括一个配体结合抗体和一个配体类似物，形成一个抗体-配体类似物复合物，其中配体类似物与一个报告分子共价结合。该复合物还可以包括一个标记蛋白，非共价结合于抗体上，形成一个三元复合物，其中标记蛋白包括单价抗体片段或共价结合于标记基团的非抗体蛋白。报告分子可以被配体结合抗体或标记蛋白的标记基团熄灭，具体取决于报告分子和配体结合抗体，其中熄灭的程度与样品中配体的数量直接相关。或者，配体类似物是荧光原性的，其中配体类似物在溶液中基本上不发荧光，但当被配体结合抗体结合时，可检测的信号增加。在这种情况下，对于目标配体的存在，测量的是信号的降低，而不是熄灭的缓解。
• Antibody complexes and methods for immunolabeling
  申请人：Beechem Joseph

  公开号：US20070269902A1

  公开（公告）日：2007-11-22

  The present invention provides labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling reagents have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Typically, the labeling reagent is an anti-Fc Fab or Fab′ fragment that was generated by immunizing a goat or rabbit with the Fc fragment of an antibody. The present invention provides for discrete subsets of labeling reagent and immuno-labeled complexes that facilitate the simultaneous detection of multiple targets in a sample wherein the immuno-labeled complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets.

  本发明提供了标记试剂和标记原初抗体的方法，以及使用包含靶向结合抗体和一种或多种标记试剂的免疫标记复合物在样品中检测目标的方法。标记试剂包括单价抗体片段或非抗体单体蛋白，其中标记试剂具有亲和力，能够与靶向结合抗体的特定区域结合，并与标记共价连接。通常，标记试剂是通过用兔子或山羊免疫抗体的Fc片段生成的抗Fc Fab或Fab'片段。本发明提供了离散的子集标记试剂和免疫标记复合物，有助于在样品中同时检测多个目标，其中免疫标记复合物通过i）标记与标记试剂的比率，或ii）标记的物理特性，或iii）标记试剂与靶向结合抗体的比率，或iv）靶向结合抗体来区分。这对于荧光标记特别有用，可以将其附加到标记试剂和随后的免疫标记复合物中，以检测多个目标。
• US7282339B2
  申请人：——

  公开号：US7282339B2

  公开（公告）日：2007-10-16
• [EN] COMPETITIVE IMMUNOASSAY<br/>[FR] DOSAGE IMMUNOLOGIQUE DE TYPE COMPETITIF
  申请人：MOLECULAR PROBES INC

  公开号：WO2005050206A2

  公开（公告）日：2005-06-02

  The present invention provides ligand-detection reagents, ligand analogs and methods for determining the presence of a ligand in a sample. The ligand-detection reagent comprises a ligand-binding antibody and a ligand analog to form an antibody-ligand analog complex wherein the ligand analog is covalently bonded to a reporter molecule. This complex may additionally comprise a labeling protein non-covalently bonded to the antibody to form a ternary complex wherein the labeling protein comprises a monovalent antibody fragment or a non-antibody protein that is covalently bonded to a label moiety. The reporter molecule is either quenched by the ligand-binding antibody or by the label moiety of the labeling protein, depending on the reporter molecule and the ligand-binding antibody, wherein the amount of quenching is directly related to the amount of ligand present in the sample. Alternatively, the ligand analog is fluorogenic wherein the ligand analog is essentially non-fluorescent in solution but when bound by the ligand-binding antibody the detectable signal increases. In this instance a decrease in signal, as opposed to the relieving of quenching, is measured for the presence of a target ligand.